Press releases

Regulatory

December 30, 2019

New number of shares and votes in Oasmia Pharmaceutical AB (publ)

Regulatory

December 30, 2019

Oasmia Pharmaceutical AB (publ) Interim report for the period May 1 – October 31, 2019

Regulatory

December 9, 2019

Final result of the rights issue in Oasmia

Regulatory

December 6, 2019

Oasmia’s rights issue has been oversubscribed

Non Regulatory

November 27, 2019

Correction: The CEO of Oasmia buys subscription rights in the ongoing rights issue

Non Regulatory

November 27, 2019

The CEO and Chairman of the Board of Oasmia buys subscription rights in the ongoing rights issue

Regulatory

November 19, 2019

Oasmia publishes prospectus in connection with the rights issue of approximately SEK 399 million and updated information included in the prospectus

Non Regulatory

November 18, 2019

Oasmia invites to investor meetings in connection to the rights issue

Regulatory

November 11, 2019

Oasmia resolves on a rights issue of approximately SEK 399 million

Regulatory

November 6, 2019

Extraordinary General Meeting in Oasmia Pharmaceutical AB on November 6, 2019

Regulatory

October 30, 2019

Oasmia recruits Michael af Winklerfelt as new CFO

Regulatory

October 14, 2019

Notice of extraordinary general meeting in Oasmia Pharmaceutical AB

Regulatory

October 14, 2019

The Board of Directors in Oasmia proposes a rights issue of approximately SEK 400 million

Regulatory

September 26, 2019

Annual General Meeting in Oasmia Pharmaceutical AB on September 26, 2019

Regulatory

September 26, 2019

Oasmia Pharmaceutical AB (publ) Interim report for the period May 1 – July 31, 2019

Regulatory

September 18, 2019

Oasmia publishes report on special investigation of liability issues conducted by audit firm Deloitte

Non Regulatory

September 18, 2019

Oasmia presents Q1 report through audiocast on September 26

Regulatory

September 15, 2019

The Nomination Committee’s proposal regarding Board of Directors and auditor of Oasmia Pharmaceutical AB for AGM 2019

Regulatory

September 5, 2019

Oasmia publishes its annual report and adjusts accounts due to write-downs

Non Regulatory

September 4, 2019

Oasmia completes its management team

Regulatory

August 28, 2019

Notice of Annual General Meeting in Oasmia Pharmaceutical AB

Non Regulatory

August 27, 2019

Oasmia updates regarding MGC disputes

Regulatory

August 23, 2019

Oasmia ADSs delisted from NASDAQ in the US

Regulatory

August 20, 2019

Nomination committee in Oasmia for the 2019 AGM

Regulatory

August 15, 2019

Oasmia postpones the release of the Q1 report to 26 September and adjusts its financial calender

Non Regulatory

August 2, 2019

Oasmia intends to delist from NASDAQ in the US to reduce complexity and costs

Regulatory

July 31, 2019

New number of shares and votes in Oasmia Pharmaceutical AB (publ)

Non Regulatory

July 9, 2019

Oasmia discontinues cooperation with former executive chairman

Regulatory

July 5, 2019

Oasmia and Arwidsro have solved outstanding balances and Arwidsro increases its investment in Oasmia

Regulatory

July 4, 2019

Oasmia appoints Business Advisory Board

Regulatory

July 2, 2019

Oasmia appoints new CMO

Regulatory

July 2, 2019

Oasmia appoints Scientific Advisory Board

Regulatory

June 28, 2019

Oasmia announces change of CEO

Regulatory

June 28, 2019

The Board of Oasmia has decided to report certain transactions to the Swedish Economic Crime Authority and to appoint a special examiner

Regulatory

June 28, 2019

Oasmia Pharmaceutical AB (publ) Year-end report for the financial year May 1, 2018 – April 30, 2019

Non Regulatory

June 26, 2019

Oasmia presents full-year report and status in the Board’s review through audiocast on June 28

Regulatory

June 25, 2019

Two studies finalized in Oasmia Pharmaceutical’s Docecal programme

Regulatory

May 15, 2019

Oasmia postpones the release of the Q4 and year-end report to 28 June

Regulatory

April 10, 2019

Oasmia expands the Management Team

Non Regulatory

April 3, 2019

Short report of the status of the review in Oasmia

Regulatory

March 29, 2019

Increase in the number of shares and votes in Oasmia Pharmaceutical AB (publ)

Non Regulatory

March 28, 2019

The results from Oasmia Pharmaceuticals first study with paclitaxel micellar in humans are published in the scientific journal ”Advances in Therapy”.

Non Regulatory

March 26, 2019

Notification from Oasmia Pharmaceutical AB

Regulatory

March 26, 2019

CFO of Oasmia, Anders Blom has resigned

Regulatory

March 25, 2019

Oasmia Pharmaceutical AB receives positive opinion from the European Medicines Agency to add efficacy data to the approved Apealea® product information

Regulatory

March 21, 2019

New Board starts reviewing the situation in Oasmia

Regulatory

March 19, 2019

Oasmia Pharmaceutical AB (publ): Press release from the extraordinary general meeting 19 March 2019

Regulatory

March 18, 2019

Oasmia announces a prospectus regarding admission to trading of new shares

Regulatory

March 6, 2019

Oasmia Pharmaceutical Strengthens its Management Team and Organization

Regulatory

March 4, 2019

Oasmia has completed a directed share issue of approximately 165 MSEK

Regulatory

March 1, 2019

Oasmia Pharmaceutical AB (publ)

Regulatory

February 5, 2019

NOTICE OF EXTRAORDINARY GENERAL MEETING IN OASMIA PHARMACEUTICAL AB (PUBL)

Regulatory

January 31, 2019

Change in the number of shares and votes in Oasmia Pharmaceutical AB (publ)

Regulatory

January 22, 2019

Oasmia Pharmaceutical AB’s (publ, ”Oasmia”) decision to cancel the extraordinary general meeting on January 25, 2019

Regulatory

January 21, 2019

Oasmia announces that the extraordinary general meeting 25 January 2019 is cancelled

Regulatory

January 15, 2019

European Medicines Agency validates Oasmia Pharmaceutical AB’s application to add efficacy data to the approved Apealea® product information